A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib.
Okamoto M, Fujimoto K, Johkoh T, Kawaguchi A, Mukae H, Sakamoto N, Ogura T, Ikeda S, Kondoh Y, Yamano Y, Komiya K, Umeki K, Nishikiori H, Tanino Y, Tsuda T, Arai N, Komatsu M, Sakamoto S, Yatera K, Inoue Y, Miyazaki Y, Hashimoto S, Shimizu Y, Hozumi H, Ohnishi H, Handa T, Hattori N, Kishaba T, Kato M, Inomata M, Ishii H, Hamada N, Konno S, Zaizen Y, Azuma A, Suda T, Izuhara K, Hoshino T.
Okamoto M, et al.
Sci Rep. 2023 Dec 27;13(1):22977. doi: 10.1038/s41598-023-49180-4.
Sci Rep. 2023.
PMID: 38151520
Free PMC article.
Monomeric and total periostin levels were not significantly associated with the change in forced vital capacity (FVC) or diffusing capacity of the lungs for carbon monoxide (D(LCO)) during any follow-up period. Higher monomeric and total periostin levels were independent r …
Monomeric and total periostin levels were not significantly associated with the change in forced vital capacity (FVC) or diffusing capacity …
